472 related articles for article (PubMed ID: 16330205)
61. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736
[TBL] [Abstract][Full Text] [Related]
62. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party.
Mead GM; Russell M; Clark P; Harland SJ; Harper PG; Cowan R; Roberts JT; Uscinska BM; Griffiths GO; Parmar MK
Br J Cancer; 1998 Oct; 78(8):1067-75. PubMed ID: 9792152
[TBL] [Abstract][Full Text] [Related]
63. [M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced renal pelvic and ureteral carcinoma].
Igawa M; Ueki T; Ueda M; Okada K; Usui T; Ohnishi Y; Kume T; Masu C; Ishino T; Nakatsu H
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2577-82. PubMed ID: 2673046
[TBL] [Abstract][Full Text] [Related]
64. [M-VAC chemotherapy for patients with lymph node metastases and/or locally advanced bladder carcinoma].
Igawa M; Ueki T; Ueda M; Okada K; Usui T; Ohnishi Y; Nakatsu H; Kume T; Kodama M; Masu C
Hinyokika Kiyo; 1989 Aug; 35(8):1323-7. PubMed ID: 2683648
[TBL] [Abstract][Full Text] [Related]
65. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature.
Long HJ; Rayson S; Podratz KC; Abu-Ghazaleh S; Suman V; Hartmann LC; Levitt R; Nair S; Hatfield AK; Knost JA
Am J Clin Oncol; 2002 Dec; 25(6):547-51. PubMed ID: 12477995
[TBL] [Abstract][Full Text] [Related]
66. [Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy].
Fukuda H; Mitsumori K; Minagawa S; Kumazawa T; Tadachi K; Iinuma M; Satoh S; Satoh K; Habuchi T; Kato T
Hinyokika Kiyo; 2005 Feb; 51(2):113-6. PubMed ID: 15773365
[TBL] [Abstract][Full Text] [Related]
67. M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
Igawa M; Kadena H; Ueda M; Usui T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S1-4. PubMed ID: 7527732
[TBL] [Abstract][Full Text] [Related]
68. M-VAC versus CisCA--chemotherapy in the treatment of advanced bladder cancer.
Heimbach D; Wirth M; Frohmüller H
Urol Int; 1992; 48(2):157-61. PubMed ID: 1585511
[TBL] [Abstract][Full Text] [Related]
69. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.
Logothetis CJ; Dexeus FH; Finn L; Sella A; Amato RJ; Ayala AG; Kilbourn RG
J Clin Oncol; 1990 Jun; 8(6):1050-5. PubMed ID: 2189954
[TBL] [Abstract][Full Text] [Related]
70. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
[TBL] [Abstract][Full Text] [Related]
71. Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen.
Sternberg CN; Yagoda A; Scher HI
Prog Clin Biol Res; 1988; 277():45-51. PubMed ID: 3054909
[No Abstract] [Full Text] [Related]
72. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
73. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.
Millikan R; Dinney C; Swanson D; Sweeney P; Ro JY; Smith TL; Williams D; Logothetis C
J Clin Oncol; 2001 Oct; 19(20):4005-13. PubMed ID: 11600601
[TBL] [Abstract][Full Text] [Related]
74. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
Dodd PM; McCaffrey JA; Herr H; Mazumdar M; Bacik J; Higgins G; Boyle MG; Scher HI; Bajorin DF
J Clin Oncol; 1999 Aug; 17(8):2546-52. PubMed ID: 10561321
[TBL] [Abstract][Full Text] [Related]
75. Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.
Langer CJ; Catalano R; Weiner LM; Scher R; Bagchi P; Saren B; Comis RL
Cancer Invest; 1995; 13(2):150-9. PubMed ID: 7874568
[TBL] [Abstract][Full Text] [Related]
76. [Clinical studies of chemotherapy for patients with a solitary kidney after nephroureterectomy for advanced upper urothelial transitional cell carcinoma].
Tsujimura A; Takayama H; Tsukikawa M; Imazu T; Sugao H; Takaha M
Hinyokika Kiyo; 1995 Mar; 41(3):183-9. PubMed ID: 7741070
[TBL] [Abstract][Full Text] [Related]
77. M-VAC or MVC for the treatment of advanced transitional cell carcinoma: metastatic, induction, and adjuvant.
Soloway MS; Ishikawa S; Taylor T; Ezell G
J Surg Oncol Suppl; 1989; 1():40-5. PubMed ID: 2765094
[TBL] [Abstract][Full Text] [Related]
78. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-Del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström A; Grande E;
Lancet; 2020 May; 395(10236):1547-1557. PubMed ID: 32416780
[TBL] [Abstract][Full Text] [Related]
79. Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy.
Bishop JR; Moul JW; Maldonado L; McLeod DG
Urology; 1990 Oct; 36(4):373-7. PubMed ID: 2219624
[TBL] [Abstract][Full Text] [Related]
80. [Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer].
Mikami K; Nakagawa S; Takada H; Ebisui K; Sugimoto K; Watanabe H; Maegawa M; Nakao M
Hinyokika Kiyo; 1994 Apr; 40(4):303-7. PubMed ID: 8191968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
